Low grade glioma: a measuring radiographic response to radiotherapy.

作者: Bauman G , Pahapill P , Fisher B , Cairncross G , Leighton C

DOI:

关键词: Survival rateMedicineCentral nervous system diseaseAstrocytomaRadiographyNuclear medicineOligodendrogliomaTumor sizeRadiation therapyLow-Grade Glioma

摘要: Purpose: We set out to determine the rate of response low-grade (WHO Grade II) gliomas radiotherapy and analyze relationship between radiographic response, symptom control patient survival. Methods: Patients were eligible for this study if they had received pathologically confirmed, residual, supratentorial astrocytoma, oligodendroglioma, or mixed glioma, imaging studies (baseline follow-up) available review . Percent change in tumor size timing determined by maximum linear measurement, area volume measurement using an ellipsoid model, vol- ume image segmentation. For each method, was defined firstly as a ‡ 50% decrease (partial response), secondly equivalent (normalized partial response). Relationships clinical improvement progression-free survival analyzed Cox Proportional Hazard's model. Results: Twenty-one patients database (13 male, 8 female; ages 22-66 years) met eligibility criteria. T wenty imaged com- puted tomography, 18 astrocytoma 15 irradiated soon after sur gery. Responses common not felt be due steroid effect. Use normalized criteria improved agreement assessment 4 methods. Median time 2.8 months (range, 1.5-11). Sixteen (76%) neurologi- cally, median progression 4.8 years 5-year 43%. W e did detect statistically significant association (as measured any method), symptomatology Conclusions: Low-grade are moderately radioresponsive. may over-estimate number responses unless reduction is used define response. The best way measure remains uncer - tain because neither visual, area, nor changes confidently predicted outcomes.

参考文章(8)
G Cairncross, D Macdonald, S Ludwin, D Lee, T Cascino, J Buckner, D Fulton, E Dropcho, D Stewart, C Schold, Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology. ,vol. 12, pp. 2013- 2021 ,(1994) , 10.1200/JCO.1994.12.10.2013
C Leighton, B Fisher, G Bauman, S Depiero, L Stitt, D MacDonald, G Cairncross, Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. Journal of Clinical Oncology. ,vol. 15, pp. 1294- 1301 ,(1997) , 10.1200/JCO.1997.15.4.1294
E Galanis, J C Buckner, P J Schomberg, J E Hammack, C Raffel, B W Scheithauer, Effective chemotherapy for advanced CNS embryonal tumors in adults. Journal of Clinical Oncology. ,vol. 15, pp. 2939- 2944 ,(1997) , 10.1200/JCO.1997.15.8.2939
R. Grant, B. C. Liang, J. Slattery, H. S. Greenberg, L. Junck, Chemotherapy response criteria in malignant glioma Neurology. ,vol. 48, pp. 1336- 1340 ,(1997) , 10.1212/WNL.48.5.1336
L. Dade Lunsford, Salvador Somaza, Douglas Kondziolka, John C. Flickinger, Survival after stereotactic biopsy and irradiation of cerebral nonanaplastic, nonpilocytic astrocytoma Journal of Neurosurgery. ,vol. 82, pp. 523- 529 ,(1995) , 10.3171/JNS.1995.82.4.0523
Harmon J. Eyre, John J. Crowley, Jeannette J. Townsend, James R. Eltringham, Robert A. Morantz, Susan F. Schulman, Joseph M. Quagliana, Muhyi Al-Sarraf, A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study Journal of Neurosurgery. ,vol. 78, pp. 909- 914 ,(1993) , 10.3171/JNS.1993.78.6.0909
S A Grossman, M Wharam, V Sheidler, L Kleinberg, M Zeltzman, N Yue, S Piantadosi, Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. Journal of Clinical Oncology. ,vol. 15, pp. 2596- 2603 ,(1997) , 10.1200/JCO.1997.15.7.2596
R Chappell, S S Miranpuri, M P Mehta, Dimension in defining tumor response. Journal of Clinical Oncology. ,vol. 16, pp. 1234- 1234 ,(1998) , 10.1200/JCO.1998.16.3.1234